Overview

Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)

Status:
Active, not recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

The CLL2-BCG-trial is a prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of a debulking with bendamustine followed by an induction with GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101-maintenance in CLL patients

Phase:

Phase 2

Details

Lead Sponsor:

German CLL Study Group

Collaborators:

Gilead Sciences
Hoffmann-La Roche

Treatments:

Bendamustine Hydrochloride
Idelalisib
Obinutuzumab